The standard problem with price discrimination, for example distributing HIV drugs for free (or marginal cost) in sub-Saharan Africa, is the drugs being diverted to consumers, say, in The West, who want to pay less. Given the price difference achievable by the monopoly (drug patents) producer, there is tremendous incentive to do this.
The problem can be solved, in principle, by adding another agent into the mix. The drug company always sells drugs at market price. It also makes donations to an organization (one or more) dedicated to providing the drugs to poor consumers, who purchases the drugs at market price (using donated funds), and the burden of making sure it is actually consumed by them is thus "outsourced". We have separated the concerns of "making as much money as possible" and "doing good for society" to separate agents.
Somehow also funded are also independent measurements that the drugs are actually being consumed by them, which the drug company uses to pick which organization to donate to. For HIV, it should be possible to measure this by who monitoring is staying well, and who is dying despite being prescribed the medication.
Inducing the drug company to donate could be done by regulation, or by some appeal to maintain a positive public image.
No comments :
Post a Comment